Multiple Sklerose: Kritische Betrachtung umstrittener und komplementärmedizinischer Therapien auf der Grundlage aktueller Hypothesen zur Pathogenese

Zusammenfassung

Die multiple Sklerose (MS) ist die häufigs-te neuroimmunologische Erkrankung, deren Ätiologie bislang noch nicht komplett geklärt ist. Obwohl mittlerweile effektive medikamentöse Therapieverfahren, die den Verlauf der Erkrankung beeinflussen, zur Verfügung stehen, benützen eine Vielzahl von MS-Patienten Therapieangebote der „komplementären Medizin”. In dieser Übersicht werden derzeit im deutschen Sprachraum angewandte alternative Therapieverfahren (Enzymtherapie u. a.) und experimentelle Behandlungsverfahren (Knochenmarktransplantation, Plasmapherese und Cannabis) vorgestellt und vor dem Hintergrund verfügbarer Erkenntnisse zur Pathogenese der MS bewertet.

Multiple Sclerosis: Critical Discussion of Controversial and Complementary Therapies Based on Current Pathogenetic Hypotheses

Multiple sclerosis (MS) represents the most frequent neuroimmunological disease with a still unknown aetiology. Although disease-modifying medications are now available, a significant fraction of MS patients make use of „complementary medicine”. This review summarises currently used complementary (polyenzyme and others) and experimental (bone marrow transplantation, plasmapheresis, and cannabis) therapeutic interventions in MS and evaluates them against the background of available knowledge of the pathogenesis of MS.

Literatur

• 1 Schwartz C E, Laitin E, Brotman S. et al . Utilisation of unconventional treatments by persons with MS: Is it alternative of complementary?.  Neurology. 1999;  52 626-629
• 2 Wang Y, Hashimoto S, Ramsum D. et al . A pilot study of the use of alternative medicine in multiple sclerosis patients with special focus on acupuncture (abstract).  Neurology. 1999;  52, Suppl 2 A550
• 3 Hartung H P, Gonsette R. and the MIMS study group . Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European phase III multicenter study-clinical results (Abstract OR 207).  Multiple Sclerosis. 1998;  4 325
• 4 Rieckmann P, Toyka K V. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG).  Eur Neurol. 1999;  42 121-127
• 5 Weilbach F X, Gold R. New treatments in multiple sclerosis: What is on the horizon.  CNS Drugs. 1999;  11 133-157
• 6 Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.  Brain. 1997;  120 865-916
• 7 Khatri B O. Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros.  Neurology. 1988;  38 50-52
• 8 Weiner H L, Dau P C, Khatri B O. et al . Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis.  Prog Clin Biol Res. 1990;  337 283
• 9  The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis.  Lancet. 1991;  337 441-446
• 10 Weinshenker B G, O'Brien P C, Petterson T M. et al . A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.  Ann Neurol. 1999;  46 878-86
• 11 Burt R K, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis.  Bone Marrow Transplant. 1995;  16 1-6
• 12 van Gelder M, van Bekkum D W. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation.  Bone Marrow Transplant. 1996;  18 1029-34
• 13 van Gelder M, van Bekkum D W. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain.  Bone Marrow Transplant. 1995;  16 343-51
• 14 Burt R K, Burns W H, Miller S D. Bone marrow transplantation for multiple sclerosis: returning to Pandoras box.  Immunol Today. 1997;  18 559-61
• 15 Burt R K, Traynor A E, Cohen B. et al . T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients.  Bone Marrow Transplant. 1998;  21 537-541
• 16 McAllister L D, Beatty P G, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis.  Bone Marrow Transplant. 1997;  19 395-7
• 17 Fassas A, Anagnostopoulos A, Kazis A. et al . Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study.  Bone Marrow Transplant. 1997;  20 631-638
• 18 Kelly P, Staunton H, Lawler M. et al . Multifocal remitting-relapsing cerebral demyelination twenty years following allogeneic bone marrow transplantation.  J Neuropathol Exp Neurol. 1996;  55 992-998
• 19 Jeffery D R, Alshami E. Allogeneic bone marrow transplantation in multiple sclerosis (abstract).  Neurology. 1998;  50, Suppl 4 A147
• 20 Euler H H, Marmont A M, Bacigalupo A. et al . Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation (see comments).  Blood. 1996;  88 3621-3625
• 21 Openshaw H, Stuve O, Antel J P. et al . Multiple sclerosis flares associated with recominant granulcyte colony-stimulating factor.  Neurology. 2000;  54 2147-2150
• 22 Haase C G, Hohlfeld R. Knochenmark- und Stammzelltransplantation bei multipler Sklerose.  Nervenarzt. 1999;  70 178-181
• 23 Comi G, Kappos L, Clanet M. et al . Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation.  BMT-MS Study Group J Neurol. 2000;  247 376-82
• 24 Kappos L, Radu E W, Haas J. et al . Deoxyspergualine in MS: a second interim analysis of the European multicentre study (Abstract).  J Neurol. 1995;  242, Suppl 2 S 23
• 25 Kappos L, Radu E W, Haas J. et al . European multicentre trial +/-deoxyspergualine (DSG) versus placebo: results of the first interim analysis (Abstract).  J Neurol. 1994;  241, Suppl 2 S27
• 26 Wirguin I, Mechoulam R, Breuer A. et al . Suppression of experimental autoimmune encephalomyelitis by cannabinoids.  Immunopharmacology. 1994;  28 209-14
• 27 Baker D, Pryce G, Croxford J L. et al . Cannabinoids control spasticity and tremor in a multiple sclerosis model.  Nature. 2000;  404 84-87
• 28 Petro D J, Ellenberger  C. Treatment of human spasticity with delta 9-tetrahydrocannabinol.  J Clin Pharmacol. 1981;  21 413S-416S
• 29 Meinck H M, Schonle P W, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.  J Neurol. 1989;  236 120-2
• 30 Weilbach F X. Marihuana als Medizin bei MS? Der ärztliche Beirat der DMSG nimmt kritisch Stellung.  AKTIV. 1998;  181 14-16
• 31 Targoni O S, Tary-Lehmann M, Lehmann P V. Prevention of murine EAE by oral hydrolytic enzyme treatment.  J Autoimmun. 1999;  12 191-198
• 32 Desser L, Rehberger A, Kokron E. et al . Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations.  Oncology. 1993;  50 403-7
• 33 Baumhackl U, Fordermair S. Enzyme therapy in multiple sclerosis. A preliminary report on a multicenter study.  Allgemeinmedizin. 1990;  19 169-172
• 34 de-Smet P A, Pegt G W, Meyboom R H. Acute circulatory shock following administration of the non-regular enzyme preparation Wobe-Mugos.  Ned Tijdschr Geneeskd. 1991;  135 2341-2344
• 35 Kiessling W R. Anaphylactic reaction in enzyme therapy of multiple sclerosis.  Fortschr Neurol Psychiatrie. 1987;  55 385-6
• 36 Liu F J, Zhang Y X, Lau B H. Pycnogenol enhances immune and haemopoietic functions in senescence- accelerated mice.  Cell Mol Life Sci. 1998;  54 1168-1172
• 37 Dworkin R H, Bates D, Millar J HD. et al . Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials.  Neurology. 1984;  34 1441-1445
• 38 Lauer K. Diet and multiple sclerosis.  Neurology. 1997;  49, Suppl 2 S55-S61
• 39 Clausen J, Jensen G E, Nielsen S A. Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's disease.  Biol Trace Elem Res. 1988;  15 179-203
• 40 Korpela H, Kinnunen E, Juntunen J. et al . Serum selenium concentration, glutathione peroxidase activity and lipid peroxides in a co-twin control study on multiple sclerosis.  J Neurol Sci. 1989;  91 79-84
• 41 Bangsi D, Ghadirian P, Ducic S. et al . Dental amalgam and multiple sclerosis: a case-control study in Montreal, Canada.  Int J Epidemiol. 1998;  27 667-71
• 42 Mertin J, McDonald W I. Hyperbaric oxygen for patients with multiple sclerosis.  Br Med J. 1984;  288 957-960
• 43 James P B. Evidence for subacute fat embolism as the cause of multiple sclerosis.  Lancet. 1982;  1 380-386
• 44 James P B. Oxygen for multiple sclerosis.  Lancet. 1983;  1 1161-1162
• 45 Kleijnen J, Knipschild P. Hyperbaric oxygen for multiple sclerosis. Review of controlled trials.  Acta Neurol Scand. 1995;  91 330-4
• 46 Toshniwal P K, Zarling E J. Evidence for increased lipid peroxidation in multiple sclerosis.  Neurochem Res. 1992;  17 205-7
• 47 Nieper H A. Klinische Untersuchungen der Kalzium-Transport-Substanzen.  Ärztl Forsch. 1966;  20 127-140
• 48 Lublin F D, Oshinsky J R, Perreault M, Siebert K. Effect of honey bee venom on EAE (abstract).  Neurology. 1998;  50, Suppl 4 A424
• 49 Pette M, Hartung H P, Toyka K V. Immune augmenting therapy as treatment of multiple sclerosis. Warning regarding a potentially toxic alternative treatment method.  Nervenarzt. 1994;  65 878-890